Sanofi (SNY) fair value analysis

Nasdaq · Updated 2026-09-07

Sanofi is a pharmaceutical company that researches, develops, manufactures, and distributes medicines and vaccines across multiple therapeutic areas including oncology, immunology, and infectious diseases. The company operates globally with a significant presence in Europe, North America, and other international markets.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, SNY is trading at a 10–25% discount to estimated fair value.

SNY currently ranks #43 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $42.95
Sector: Healthcare
12-month range: $41.63–$47.40

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: B
Leverage: Low
Margin trend: Expanding
Revenue growth: Modest
RSI zone: Neutral
50/200-day trend: Downtrend
52-week position: The bottom quarter of its range
DCF cross-check: Undervalued

What our data shows for SNY

Our model validated 17 trailing price-to-earnings windows for SNY, built from quarterly earnings records.
Shares are trading in the lower third of their 12-month price range of $41.63–$47.40.
The 14-day relative strength index sits at a neutral 57.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for SNY
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent SNY news

TickrTrends' derived news-sentiment signal for SNY is currently mixed, computed from recent coverage.

Sanofi: Trump’s Vaccine Policy Won’t Break The Story (NASDAQ:SNY) (seekingalpha.com, 2026-08-24)
TickrTrends take: Sanofi operates in the Healthcare sector where policy shifts can materially affect revenue streams and investor perception of growth prospects. The Trump administration's vaccine policy positions represent a factor that valuation models must monitor, as changes to vaccine procurement, distribution, or reimbursement could influence the company's future earnings trajectory. TickrTrends currently assesses SNY as undervalued, suggesting the market may not yet have fully priced in the company's ability to navigate policy uncertainties while maintaining its core business fundamentals.
Why the Amlitelimab Setback Isn’t Enough to Sink Sanofi’s Multi-Billion Dollar Engine (insidermonkey.com, 2026-08-10)
TickrTrends take: Sanofi faces a setback with amlitelimab, a program within its broader pipeline, though the company maintains multiple revenue-generating assets across its healthcare operations. TickrTrends currently indicates the stock is undervalued relative to its fundamentals, suggesting that isolated pipeline challenges may not fully diminish the company's overall financial engine. Investors focused on valuation metrics should monitor how Sanofi allocates resources toward its remaining programs and whether near-term revenue from established products can offset any development delays.

What people are saying

Follow the SNY conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — # SNY - Sanofi TickrTrends' derived indicators for SNY shifted this week, with the DCF cross-check band moving from overvalued to undervalued territory. This change aligns with the current valuation verdict of undervalued for the healthcare sector company. The shift suggests that SNY's valuation metrics have moved to indicate the stock may be trading below its fundamental value estimates.
2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is SNY stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), SNY is trading at a 10–25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is SNY's TickrTrends verdict?

SNY's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does SNY compare to other Healthcare stocks?

SNY ranks #43 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is SNY overbought or oversold?

SNY's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

SNY vs ABT · SNY vs BTSG · SNY vs COLL · SNY vs DVA · SNY vs EXEL